
Humacyte, Inc. (NASDAQ:HUMA – Free Report) – HC Wainwright lowered their FY2029 earnings estimates for shares of Humacyte in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.07 for the year, down from their previous estimate of $0.09. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Humacyte’s FY2030 earnings at $0.29 EPS.
Other equities analysts have also issued reports about the stock. Cantor Fitzgerald set a $1.00 target price on shares of Humacyte in a research note on Thursday. BTIG Research reissued a “buy” rating and issued a $2.00 price target on shares of Humacyte in a research note on Tuesday. Barclays boosted their price target on Humacyte from $0.50 to $0.60 and gave the company an “equal weight” rating in a report on Wednesday. Williams Trading set a $1.00 price objective on Humacyte in a research report on Friday, October 16th. Finally, Wall Street Zen upgraded Humacyte to a “sell” rating in a report on Saturday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and an average target price of $4.48.
Humacyte Trading Down 6.2%
Shares of NASDAQ:HUMA opened at $0.56 on Thursday. The firm has a market cap of $155.12 million, a price-to-earnings ratio of -1.27 and a beta of 2.64. Humacyte has a 12 month low of $0.34 and a 12 month high of $1.52. The company’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.78. The company has a quick ratio of 5.74, a current ratio of 3.34 and a debt-to-equity ratio of 3.65.
Humacyte (NASDAQ:HUMA – Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). Humacyte had a negative net margin of 3,955.05% and a negative return on equity of 612.88%. The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million.
Institutional Investors Weigh In On Humacyte
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. bought a new position in shares of Humacyte in the 2nd quarter valued at about $4,700,000. BlackRock Inc. bought a new stake in Humacyte during the second quarter worth about $3,777,000. Marshall Wace LLP boosted its position in Humacyte by 1,548.0% during the third quarter. Marshall Wace LLP now owns 2,996,553 shares of the company’s stock valued at $1,558,000 after purchasing an additional 2,814,722 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Humacyte during the second quarter valued at approximately $785,000. Finally, HBK Investments L P acquired a new position in Humacyte during the second quarter valued at approximately $617,000. 44.71% of the stock is owned by institutional investors.
Trending Headlines about Humacyte
Investors following HUMA have been watching these headlines:
- Positive Sentiment: HC Wainwright raised its estimated loss per share for FY2026 to $0.39 from $0.46, and narrowed its projected losses for Q4 2026 and Q1 2027. The firm maintained its Buy rating.
- Positive Sentiment: StoneX reiterated its Speculative Buy rating, while a separate roundup highlighted Humacyte among healthcare stocks with bullish analyst views. StoneX Reiterates Speculative Buy Rating on Humacyte Analysts Are Bullish on These Healthcare Stocks
- Negative Sentiment: HC Wainwright trimmed estimates for FY2027 and FY2028, and lowered projected Q3 and Q4 2027 results. It now expects a $0.31-per-share loss in FY2027 and a $0.11 loss in FY2028, signaling a slower path to profitability than previously forecast.
Humacyte Company Profile
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.
Recommended Stories
- Five stocks we like better than Humacyte
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
